Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
WALTHAM, Mass., March 01, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Pain Society (APS) Annual Scientific Meeting to be held in Anaheim, CA, March 4-6.
The study leveraged the Quell® Health Cloud, which connects with the Quell wearable pain relief device and its companion smartphone app. The cloud database stores the user's demographic and clinical profile, health metrics including pain, sleep, activity and gait, and device utilization. The Quell Health Cloud has over fifty thousand registered Quell users and is rapidly becoming one of the largest chronic pain databases in the world. The scientific poster is titled "Dose-Response of Surface Neurostimulation in Chronic Pain.”
"Chronic pain is a complex biopsychosocial condition that requires a customized treatment approach. Our vision is to leverage the unique data assets we are collecting in the Quell Health Cloud to deliver personalized pain relief for our customers," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are particularly interested in how therapeutic dose impacts Quell effectiveness. The data that will be presented at APS was from over 4000 Quell users and shows that daily use yields the greatest improvement in pain intensity and pain interference with function. We are in the process of translating these findings into actionable directions for Quell users.”
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
Source: NeuroMetrix, Inc.
